Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80

​Alvotech (NASDAQ:ALVO) is one of the Best Penny Stocks That Will Skyrocket. On February 5, Alvotech (NASDAQ:ALVO) announced strong initial results from a key clinical trial for AVT80. AVT80 is a potential biosimilar to the blockbuster drug, Entyvio, from Takeda. ​Management noted that the randomized, double-blind study successfully fit all primary goals, including proving AVT80 matches Entyvio’s pharmacokinetics. The trial also passed all safety, tolerability, and immune response criteria. ​“We are very ...